Related Experiment Video
Updated: Aug 23, 2026
Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
Published on: April 10, 2026
[Effectiveness and tolerability of amisulpride in patients with schizophrenia: results of a 6-month open study]
Małgorzata Rzewuska1, Wojciech Kuczyński, Małgorzata Luks
1Samodzielnej Pracowni Farmakoterapii IPiN w Warszawie.
Aim:
6-month multicentre, observational, open study evaluated the efficacy and tolerability of the new generation antipsychotic drug amisulpride in patients with acute schizophrenia.
Method:
99 patients were included in the study, 72 (72%) completed the 6-month observation.
Results:
Marked improvement in CGI after 6 months of treatment was observed in 56 (56%) patients. Therapy with amisulpride reduced both positive (20% reduction of positive symptoms in the PANSS positive subscale in 78%) and negative symptoms (20% reduction of negative symptoms in the PANSS negative subscale in 77%).
Conclusion:
Amisulpride was well tolerated, adverse events responsible for premature withdrawal from the study were observed only in 6% patients.